Skip to main content

Wonder Drug

Scientists Finally Crack 60-Year Mystery Behind Diabetes ‘Wonder Drug’ Metformin



The antidiabetic drug metformin, widely prescribed for managing Type 2 diabetes, has long been recognized for its capacity to reduce blood glucose levels, attenuate inflammation, and slow tumor progression. Despite its widespread use for over 60 years, the precise molecular mechanisms underlying its effects have remained unclear.

A recent study from Northwestern Medicine, published in Science Advances, sheds light on this longstanding question by identifying mitochondrial complex I as a primary target of metformin.
Targeting Mitochondria To Regulate Blood Sugar

Metformin exerts its glucose-lowering effects by disrupting energy production within the mitochondria, a key organelle responsible for cellular metabolism. The study demonstrates that the drug inhibits mitochondrial complex I, a crucial component of the mitochondrial electron transport chain. This disruption impairs cellular energy production in select cell types, including those implicated in disease, while sparing healthy cells.

“While millions of people take metformin, its mechanism of action has remained enigmatic,” said Navdeep Chandel, senior author and professor of medicine and biochemistry at Northwestern University Feinberg School of Medicine. “This research provides clear evidence that metformin lowers blood glucose levels by targeting mitochondrial complex I.”

The Experimental Approach: Using Genetically Engineered Mice


The team conducted experiments on genetically engineered mice expressing NDI1, a yeast-derived enzyme that mimics the function of complex I but is resistant to metformin. By comparing glucose levels in mice treated with metformin, the study uncovered the following key findings:

In wild-type mice, metformin significantly reduced blood glucose levels.
Mice expressing NDI1 exhibited reduced sensitivity to metformin, with a less pronounced decrease in blood glucose levels.

The partial resistance observed in NDI1-expressing mice suggests additional pathways may contribute to metformin’s glucose-lowering effects.

This work builds on earlier research showing metformin’s ability to inhibit mitochondrial complex I in cancer cells, potentially slowing tumor growth.

Metformin’s Broad Applications and Future Research

Metformin’s benefits extend beyond diabetes management. Research has linked it to:Cancer therapy: Inhibiting complex I in cancer cells.

Inflammation reduction: Alleviating pollution-induced inflammation in studies with mice.

COVID-19 outcomes: Preliminary studies suggest metformin might improve survival rates.

These results strongly implicate mitochondrial complex I as a critical target of metformin in glucose regulation. Furthermore, earlier research from the Chandel lab demonstrated that metformin’s inhibition of complex I also contribute to its anti-cancer effects in cells expressing metformin transporters.

“We believe the diverse effects of metformin—ranging from glucose regulation to inflammation reduction and potential anti-cancer properties—can be partially explained by its inhibition of mitochondrial complex I,” Chandel said. He emphasized the need for further research to corroborate these findings and explore additional mechanisms.

A Historic Drug With a Modern Understanding

Metformin, derived from compounds in the French lilac plant, has been a cornerstone of diabetes management since its introduction more than six decades ago. Its low cost and efficacy make it a first-line therapy for millions of patients worldwide. In the United States, it is frequently used alongside newer antidiabetic medications, including semaglutides like Ozempic and Mounjaro.

The drug’s multifaceted effects have prompted numerous hypotheses about its mechanisms over the years. However, many of these theories have lacked definitive experimental evidence or consensus within the scientific community.

What Lies Ahead

The identification of mitochondrial complex I as a primary target of metformin opens new avenues for research. By elucidating the specific pathways involved in its action, scientists can refine therapeutic strategies for diabetes and potentially extend metformin’s application to other diseases.

“Metformin’s interaction with mitochondrial complex I offers a cohesive explanation for its effects across multiple conditions,” Chandel noted. “This understanding provides a foundation for further exploration into how targeting mitochondria can enhance human health.”

This study not only resolves a decades-old question about metformin’s mechanism of action but also underscores the potential of mitochondrial biology as a focal point for developing novel therapeutic interventions.

innovative medicine, breakthrough therapy, pharmacological marvel, targeted treatment, next-generation drug, therapeutic agent, medical innovation, FDA approval, revolutionary cure, clinical trials, life-saving medication, drug efficacy, pharmaceutical development, chronic disease management, advanced therapy, biotechnology, precision medicine, health transformation, drug discovery, patient outcomes

#WonderDrug, #MedicalBreakthrough, #PharmaceuticalInnovation, #RevolutionaryTreatment, #DrugDiscovery, #LifeChangingMedicine, #AdvancedTherapy, #PrecisionMedicine, #InnovativeHealthcare, #ClinicalTrials, #HealthCareSolutions, #TargetedTherapies, #NextGenMedicine, #TherapeuticAdvancement, #CureInnovation, #BiotechSolutions, #LifeSaver, #ChronicDiseaseTreatment, #MedicalAdvances, #FutureOfHealth

International Conference on Genetics and Genomics of Diseases 

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more